Galapagos to Present, Contributing to Five Posters at North American Cystic Fibrosis Conference

Galapagos NV

is present with a strong delegation presenting or contributing to five posters at the North American Cystic Fibrosis Conference (NACFC) in Phoenix this week. Thursday, 8 October 11.50 AM - 1.50 PM MSTAll postersFriday, 9 October 7.30 AM - 8.45 AM Poster 50 Potentiators: how do they impact the fate of CFTR during biogenesis?Insights are presented on the contribution of GLPG1837 to the rescue of F508del CFTR Poster 70Insight into the mechanisms of correctors and potentiatorsGalapagos and Abbvie developed new tools to better understand the mechanism of action of correctors and potentiators in its CF portfolio Poster 62Using BLISS analysis to categorize corrector-corrector interactionsGalapagos and AbbVie disclose the usage of a modelling tool to categorize interactions between candidate corrector compounds in their CF program Poster 258Safety, tolerability and pharmacokinetics of a novel CFTR Potentiator GLPG1837 in healthy volunteersGalapagos presents safety and tolerability of GLPG1837 in healthy human volunteers, paving the path for the Phase 2 study in Class III mutation patients to